Xeltis recently announced that the FDA has granted Breakthrough Device designation for the company’s aXess vascular acce ...

Simcere Pharmaceuticals Group Ltd. recently announced that findings from the TASTE-2 clinical study have shown that the admini ...

Healionics Corporation announced that its Stargraft arteriovenous (AV) graft for dialysis access has been granted ...

Arsenal Medical announced the initiation of the EMBO-02 clinical study of its NeoCast liquid embolic to treat chronic ...

Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the compa ...

November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...

The final results from the DETOUR2 study evaluated the durability of percutaneous transmural arterial bypass (PTAB) using the D ...